Peptides That Could Stop Toxic Protein Clumping in Huntington's Disease

The screened inhibitory peptides suppressed fibril formation in mutant huntingtin (mHtt) protein fragments, including both Htt(Q46) and Htt(Q103) — forms with 46 and 103 CAG repeats respectively. The Thioflavin T (ThT) fluorescence assay confirmed reduced fibril kinetics, and atomic force microscopy (AFM) imaging showed that the peptides prevented the characteristic fibril structures from assembling.

Inhibitory peptides were screened against monomeric units of wild-type huntingtin (Htt(Q25)) and two mutant fragments (Htt(Q46) and Htt(Q103)). Fibril formation kinetics were measured using the Thioflavin T (ThT) fluorescence assay, a standard method for detecting amyloid-like fibrils. Atomic force microscopy (AFM) was used to visualize how the peptides affected fibril morphology at the nanoscale.

There is no cure for Huntington's disease and current treatments only manage symptoms. Preventing the toxic protein aggregation that drives neurodegeneration could fundamentally change how the disease is treated. Peptide-based therapies are particularly promising because they can be designed to specifically target the aggregation-prone regions of mutant huntingtin.

Protein aggregation is a hallmark of multiple neurodegenerative diseases including Alzheimer's, Parkinson's, and Huntington's. Peptide-based aggregation inhibitors represent an emerging class of potential therapeutics. If these candidates can be optimized for brain delivery and tested in animal models, they could advance toward clinical development for a disease with no disease-modifying treatment.

This is an in vitro (test tube) study only — no cell-based or animal model data were presented. The peptides have not been tested for brain penetration, stability in biological fluids, or toxicity. The jump from blocking fibril formation in a lab assay to slowing disease progression in humans is substantial and would require extensive further research.